Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1314151617181920212223...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update. (Hall A; Poster Bd #: 364) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_885;    
    Updated results confirmed that the combination of pembrolizumab plus lenvatinib as neoadjuvant therapy had moderate anti-tumor efficacy in resectable mucosal melanoma. Increased CD8+ T cell infiltration was observed in tumor with pathologic response, supporting further investigation in mucosal melanoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti (Hall A; Poster Bd #: 343) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_867;    
    P2
    MPR pts had a significant increase in the number of lymphoid aggregates at week 6 compared to non-MPR pts; however, the role of these lymphoid aggregates, including the follicular B helper T cell subset and mature B cells, promoting a good pathological response to neoIT is yet to be clarified. With over 4 years of follow up, len + pembrocontinued to show antitumor activity in pts with advanced melanoma and confirmed progression after ?2 doses of anti
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. (Hall A; Poster Bd #: 307) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_833;    
    FDG-PET demonstrates utility in predicting pathological response and survival with neoadjuvant immunotherapy in melanoma. PET may identify pts who are not going to be pathological responders and who have the worst survival outcomes, enabling a potential switch of neoadjuvant systemic therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Triplet combination treatments with pembrolizumab (pembro) for anti (Hall D1) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_824;    
    P1/2
    We report results from arm 1 (pembro + quavonlimab [qmab] (anti-CTLA4) + vibostolimab [vibo] (anti-TIGIT)), arm 2 [pembro + qmab + lenvatinib [len] (TKI)), and arm 3 (pembro + ATRA [all-trans retinoic acid]) of KEYMAKER-U02A. Although objective responses were observed in some pts with anti
  • ||||||||||  Clinical, Retrospective data, Review, Journal, Metastases:  The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. (Pubmed Central) -  Apr 22, 2024   
    Concerning OS benefits, sintilimab plus bevacizumab biosimilar (Sint?+?Beva), camrelizumab plus rivoceranib (Camre?+?Rivo), and lenvatinib plus pembrolizumab (Lenva?+?Pemb) appear to exhibit similar effects to Tre?+?Du and Atezo?+?Beva...With lower incidence rates of treatment-related adverse events and non-inferior efficacy compared to sorafenib, ICI monotherapies should be prioritized as a first-line treatment approach for patients who are not suitable candidates for ICI-combined therapies. PROSPERO, CRD42022288172.
  • ||||||||||  Enrollment open:  CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) -  Apr 18, 2024   
    P3,  N=1250, Recruiting, 
    Our findings suggest a clinically relevant effectiveness of lenvatinib plus everolimus combination with an acceptable toxicity profile for heavily pretreated patients with mRCC. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Observational data, Journal, PD(L)-1 Biomarker:  Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study. (Pubmed Central) -  Apr 17, 2024   
    The sensitivity and specificity of these biomarkers were 85.71% and 70.59%, and 85.71% and 85.71%, respectively. The proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as both a prognostic marker of response to immunotargeted therapy and a prognostic factor for progression-free survival in patients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Apr 16, 2024   
    P1,  N=11, Active, not recruiting, 
    Our network meta-analysis showed that we believe that cabozantinib has the potential to become a widely used drug in clinical practice. Trial completion date: Sep 2024 --> Jun 2028
  • ||||||||||  New P3 trial:  CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) -  Apr 14, 2024   
    P3,  N=1250, Not yet recruiting, 
  • ||||||||||  Inlyta (axitinib) / Pfizer, AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. (Pubmed Central) -  Apr 12, 2024   
    On the contrary, some patients with mucosal, acral or KIT-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.
  • ||||||||||  Review, Journal:  Update of the German S3 guideline on renal cell carcinoma (Pubmed Central) -  Apr 11, 2024   
    Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma. The S3
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  LENVABLA: Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (clinicaltrials.gov) -  Apr 8, 2024   
    P2,  N=32, Active, not recruiting, 
    N=47 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=50 --> 32 | Trial completion date: Feb 2025 --> Oct 2026 | Trial primary completion date: Apr 2024 --> Jul 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. (Pubmed Central) -  Apr 3, 2024   
    Therapeutically, significant and durable tumor regression and survival benefit were achieved with 177Lu- and 225Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts. Preclinical in